Clinical trials · New York
Sarcoma clinical trials in New York
We’re tracking 54 recruiting sarcoma studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
New York, New YorkAges 1–30 - NCT04305691RecruitingPhase 2
Ixazomib for skin Kaposi sarcoma in people with HIV
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
New York, New YorkAges 18 years+ - NCT04031677RecruitingPhase 3
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
Buffalo, New YorkAges 18 years+ - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
New York, New YorkAges 12–85 - NCT03465592RecruitingPhase 1/Phase 2
Nivolumab after mismatched bone marrow transplant for sarcoma
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
The Bronx, New YorkAges 1–40 - NCT01659203RecruitingPhase 1/Phase 2
Proton or photon radiation for retroperitoneal sarcoma
This trial tests two types of external beam radiation—protons or photons—in people with retroperitoneal (in the back of the abdomen) soft tissue sarcoma. It’s an early-phase study meant to see how well the radiation can control measurable tumors while tracking safety.
Buffalo, New YorkAges 18 years+ - NCT00579566Recruiting
Research study using removed tissue from soft-tissue sarcoma
This study looks at tissue (samples taken during diagnosis or treatment) to learn new biological and molecular clues about soft-tissue sarcoma. Participating mainly helps researchers collect usable tissue that would otherwise be discarded.
Commack, New YorkAges Any age - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
New York, New YorkAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
New York, New YorkAges 16 years+ - NCT07194044RecruitingPhase 1
Testing a treatment schedule for metastatic Ewing sarcoma
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
The Bronx, New YorkAges 1 year+ - NCT07104331RecruitingPhase 2
Testing nab-sirolimus for epithelioid hemangioendothelioma
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
New York, New YorkAges 18 years+ - NCT06946225RecruitingPhase 1
Combination cell therapy for advanced melanoma or sarcoma
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
New York, New YorkAges 18 years+ - NCT06892678RecruitingPhase 1/Phase 2
DFMO maintenance for relapsed Ewing sarcoma or osteosarcoma
This trial tests a drug called DFMO given as maintenance therapy to keep cancer from coming back. It is for people under 40 who have finished treatment for relapsed Ewing sarcoma or osteosarcoma and currently show no signs of cancer.
The Bronx, New YorkAges Up to 39 years - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
New York, New YorkAges 18–90 - NCT05135975RecruitingPhase 2
Cabozantinib maintenance to help stop pediatric cancer from growing
This trial studies cabozantinib given after standard treatment to try to keep high-risk pediatric solid tumors from coming back or getting worse. It is offered to children and young adults whose cancer has not fully disappeared but is not progressing at the start of this maintenance phase.
The Bronx, New YorkAges 1.5 years–40 years - NCT06644755RecruitingPhase 1
First-in-human study of DS-2243a for advanced cancers
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
New York, New YorkAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
New York, New YorkAges 6 months–25 years - NCT04079179RecruitingPhase 2
Cobimetinib for difficult Langerhans cell and similar disorders
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
New York, New YorkAges Any age - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Lake Success, New YorkAges 18 years+ - NCT06021626RecruitingPhase 1
Study of CRD3874-SI for advanced solid tumors
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Rockville Centre, New YorkAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Commack, New YorkAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Commack, New YorkAges 18 years+ - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
New York, New YorkAges 18 years+ - NCT05642455RecruitingPhase 1/Phase 2
Study of a new treatment for certain childhood cancers
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
New York, New YorkAges 2–21
Sarcoma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting sarcoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 12 studies
- Roswell Park Comprehensive Cancer Center · 4 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Memorial Sloan Kettering Westchester · 3 studies
- Montefiore Medical Center · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Albert Einstein College of Medicine, Children's Hospital at Montefiore
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital
What taking part in a sarcoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Sarcoma trials in other states
Common questions
- Are there sarcoma clinical trials in New York?
- Yes. We're currently tracking 54 recruiting sarcoma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a sarcoma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a sarcoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New sarcoma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.